Your browser doesn't support javascript.
loading
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Birdwell, K A; Decker, B; Barbarino, J M; Peterson, J F; Stein, C M; Sadee, W; Wang, D; Vinks, A A; He, Y; Swen, J J; Leeder, J S; van Schaik, Rhn; Thummel, K E; Klein, T E; Caudle, K E; MacPhee, I A M.
Afiliação
  • Birdwell KA; Division of Nephrology Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Decker B; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Barbarino JM; Division of Nephrology and Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Peterson JF; Department of Genetics, Stanford University, Stanford, California, USA.
  • Stein CM; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Sadee W; Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, USA.
  • Wang D; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Vinks AA; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
  • He Y; Center for Pharmacogenomics, School of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Swen JJ; Center for Pharmacogenomics, School of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Leeder JS; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • van Schaik R; Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
  • Thummel KE; Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, Peoples Republic of China.
  • Klein TE; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Caudle KE; Division of Clinical Pharmacology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
  • MacPhee IA; Department of Clinical Chemistry, Erasmus MC Rotterdam, The Netherlands.
Clin Pharmacol Ther ; 98(1): 19-24, 2015 Jul.
Article em En | MEDLINE | ID: mdl-25801146
ABSTRACT
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tacrolimo / Citocromo P-450 CYP3A / Imunossupressores Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tacrolimo / Citocromo P-450 CYP3A / Imunossupressores Idioma: En Ano de publicação: 2015 Tipo de documento: Article